Characteristics of patients (pts) with disease relapse despite absence of molecular residual disease (MRD) after resection of colorectal oligometastases (CRM): Implications from PRECISION study.
Shin Kobayashi(National Cancer Center Hospital East), Yoshiaki Nakamura(National Cancer Center Hospital East), Takeshi Takamoto(Tokyo National Hospital), Yoshinori Kagawa(Osaka International Cancer Institute), Soichiro Natsume(Tokyo Metropolitan Komagome Hospital), Daisuke Nobuoka(Fukuyama City Hospital), Manabu Shiozawa(Kanagawa Prefectural Hospital Organization), Eiji Oki(Kyushu University), Akio Shiomi(Shizuoka Cancer Center), Akinobu Taketomi(Hokkaido University), Takefumi Niguma(Okayama Saiseikai General Hospital), Takeshi Kato(Osaka National Hospital), Amane Takahashi(Saitama Cancer Center), Yu Takahahshi(Japanese Foundation For Cancer Research), Satoru Kani, Yasuhiro Shimizu(Aichi Cancer Center), Junichiro Yamauchi(Sendai Kousei Hospital)
Cited by 0
Related Papers
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
|Nature Reviews Clinical Oncology|2021|301
Interleukin‐6/<scp>STAT</scp>3 signaling as a promising target to improve the efficacy of cancer immunotherapy
|Cancer Science|2017|295
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
|Nature Medicine|2018|282